Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 36
1997 89
1998 102
1999 102
2000 147
2001 129
2002 162
2003 180
2004 200
2005 191
2006 176
2007 215
2008 182
2009 186
2010 165
2011 164
2012 181
2013 152
2014 102
2015 111
2016 123
2017 90
2018 79
2019 76
2020 62
2021 39
2022 45
2023 36
2024 56
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,337 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Suárez-García I, Alejos B, Hernando V, Viñuela L, Vera García M, Rial-Crestelo D, Pérez Elías MJ, Albendín Iglesias H, Peraire J, Tiraboschi J, Díaz A, Moreno S, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. J Antimicrob Chemother. 2023 Jun 1;78(6):1423-1432. doi: 10.1093/jac/dkad102. J Antimicrob Chemother. 2023. PMID: 37099559 Free PMC article.
Lamivudine-Associated Lactic Acidosis.
Konala VM, Adapa S, Dinesh KP, Agrawal N, Naramala S, Dhingra H, Aronow WS. Konala VM, et al. Am J Ther. 2022 Jul 1;29(4):449-451. doi: 10.1097/MJT.0000000000000922. Am J Ther. 2022. PMID: 35622009 No abstract available.
Adefovir for lamivudine-resistant hepatitis B.
Roediger R, Smyth EK, Dieterich D. Roediger R, et al. Antivir Ther. 2022 Apr;27(2):13596535211067605. doi: 10.1177/13596535211067605. Antivir Ther. 2022. PMID: 35499182 Free article. Review.
Lamivudine-induced paronychia.
Zerboni R, Angius AG, Cusini M, Tarantini G, Carminati G. Zerboni R, et al. Lancet. 1998 Apr 25;351(9111):1256. doi: 10.1016/S0140-6736(05)79324-7. Lancet. 1998. PMID: 9643757 No abstract available.
Lamivudine-associated thrombocytopenia.
Lebensztejn DM, Kaczmarski M. Lebensztejn DM, et al. Am J Gastroenterol. 2002 Oct;97(10):2687-8. doi: 10.1111/j.1572-0241.2002.06063.x. Am J Gastroenterol. 2002. PMID: 12385471 No abstract available.
Clinical pharmacokinetics of lamivudine.
Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Johnson MA, et al. Clin Pharmacokinet. 1999 Jan;36(1):41-66. doi: 10.2165/00003088-199936010-00004. Clin Pharmacokinet. 1999. PMID: 9989342 Review.
Lamivudine for the treatment of HIV.
Kumar PN, Patel P. Kumar PN, et al. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):105-14. doi: 10.1517/17425250903490418. Expert Opin Drug Metab Toxicol. 2010. PMID: 20001611 Review.
3,337 results